Stockreport

Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis [Yahoo! Finance]

ROCHE HOLDING LTD S/ADR  (RHHBY) 
NASDAQ:AMEX Investor Relations: roche.com/investors.htm
PDF The trial did not meet its primary endpoint; results support Ocrevus IV 600 mg as the optimal dose to slow disability progression - High dose was well tolerated with [Read more]